What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 9,786,973 | $634,293,721 | -4% | 3.78% |
| 2. | Orbis Investment Management William B. Gray | 4,982,085 | $322,888,929 | +81% | 1.39% |
| 3. | SR One Capital Simeon George | 2,038,763 | $132,132,230 | +95% | 19.11% |
| 4. | EcoR1 Capital Oleg Nodelman | 1,389,276 | $90,038,978 | 4.32% | |
| 5. | 888,000 | $57,551,280 | +203% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $57.03 | 20,000 | $1,140,600.00 | 22,000 | 2025-08-06 | Filing | |
| $52.03 | 960,983 | $49,999,945.49 | 1,730,179 | 2025-07-16 | Filing | |
| $52.03 | 22,319 | $1,161,257.57 | 238,897 | 2025-07-16 | Filing | |
| $52.03 | 6,510 | $338,715.30 | 69,687 | 2025-07-16 | Filing | |
| $44.85 | 7,000 | $313,947.90 | 7,000 | 2025-02-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $67.91 | 50,895 | $3,456,279.45 | 254,201 | 2025-10-17 | Filing | |
| $66.60 | 4,242 | $282,517.20 | 205,096 | 2025-10-14 | Filing | |
| $66.60 | 1,076 | $71,661.60 | 83,402 | 2025-10-14 | Filing | |
| $58.15 | 13,081 | $760,660.15 | 207,004 | 2025-08-18 | Filing | |
| $35.94 | 3,932 | $141,316.08 | 6,068 | 2025-05-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,050,145 | $456,919,897 | 0.01% | |
| 2. | 5,649,258 | $366,128,411 | 0.06% | |
| 3. | 4,007,233 | $259,708,771 | 0.01% | |
| 4. | 2,364,645 | $153,252,642 | 0% | |
| 5. | 2,339,056 | $151,594,219 | 0.02% |
News See All
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now.
Cathie Wood's Stock Portfolio: Top 10 Stocks to Buy
Catherine “Cathie” Wood has been leading the investment management firm ARK Investment Management LLC ("ARK Invest") as its Founder, CEO, and CIO for nearly 15 years.
12 Best Short Squeeze Stocks to Buy Right Now
As the year comes to a close, investors are keeping close tabs on the Federal Reserve's impending policy move, given the US shutdown-induced data shortage.
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy.
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP) Stock
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C.
Hedge Fund Resource Center Billionaire Hedge Funds
